PROGRAMME AT A GLANCE Time Wednesday 5 May 2021 Thursday 6 May 2021 Friday 7 May 2021 (CET) Side-meetings: Side-meeting: 09:30-11:00 EATG stakeholder meeting 10:00-13:00 CET, COBATEST network 09:30-14:30 regarding diagnostics executive meeting, Closed meeting 11:30-13:00 Lisbon Fast Track City 13:30-14:30 European Fast-Track Cities Plenary/abstract-driven session: Impact of COVID-19 on prevention and testing Plenary session: Implementing integrated 13:00-14:15 services for HIV, viral hepatitis, STIs and TB: testing strategies Building back better Abstract driven session: The use of new Abstract driven session: Models of testing 14:30-15:30 15:00-17:00 Opening session technologies to increase testing coverage and linkage to care for PWID and PWUD 15:30-16:30 E-poster sessions (live Q&A)/Break E-poster sessions (live Q&A)/Break Plenary session: Combination prevention in Plenary session: Special Session on people 16:30-17:45 HIV, viral hepatitis, STIs and TB who inject/use drugs (EMCDDA/ECDC)

18:00-19:15 Closing session: Integrating 18:00-19:30 EU Health Project Symposium: 18:00-19:30 disease areas and settings: Paving the way lessons learned from INTEGRATE forward

1

Wednesday 5 May 2021

Time (CET) Side meetings 09:30-11:00 EATG stakeholders meeting regarding diagnostics 11:30-13:00 Lisbon Fast Track City: HCV testing and treatment in the community – learning from harm reduction and people who use drugs 13:30-14:30 Fast-Track Cities: Actioning HCV Elimination in European Urban Settings Time (CET) Presen Session Moderators and speakers tation No. Moderators: Daniel Simões, HepHIV2021 Conference Co-chair, 15:00-17:00 OS OPENING SESSION Coalition Plus/GAT, Portugal Jürgen Rockstroh, HepHIV2021 Conference Co-chair, HIV Outpatient Clinic, University of Bonn, 15:00-15:10 OS/00 Welcome to the HepHIV 2021 Lisbon & Virtual Conference Ricardo Baptista Leite, Local conference co-chair, MP Portugal, UNITE 15:10-15:20 OS/01 Conference objectives and overview Dorthe Raben, EuroTEST Initiative, CHIP, University of Copenhagen 15:20-15:30 OS/02 Welcome message from the Portuguese Minister of Health António Lacerda Sales, Assistant State Secretary for Health, Portugal 15:30-15:40 OS/03 Welcome from the : The EU response on HIV, viral hepatitis, STIs and TB in the future John Ryan, Director of Public Health, DG Sante, European Commission 15:40-15:50 OS/04 Post-2020/COVID-19 and progress towards the SDG targets: Where are we? Andrea Ammon, Director, European Centre for Disease Prevention and Control (ECDC) 15:50-16:00 OS/05 ‘The changed landscape’ – providing testing for HIV/STIs/hepatitis/TB in the era of COVID-19 Hans Kluge, Regional Director, WHO Regional Office for . Represented by Nicole Seguy, WHO Regional Office for Europe in the live discussion 16:00-16:10 OS/O6 Country Spotlight: Portugal’s progress in reaching the global targets and interventions for integration of Rui Portugal, Deputy Director-General of Health, National testing Directorate of the Portuguese Ministry 16:10-16:20 OS/07 Community perspective on enabling environments for integrated testing and linkage to care across Europe Daniel Simões, Coalition Plus/GAT, Portugal 16:20-17:00 Panel discussion

2

Thursday 6 May 2021

Time (CET) Session Moderators and speakers Moderators: PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: Impact of COVID-19 on prevention and Nicole Seguy, WHO Regional office for Europe 13:00-14:15 PS1 testing services for HIV, viral hepatitis, STIs and TB: Building back better Jeffrey Lazarus, Barcelona Institute for Global Health (IS Global) Keynote Address H.Clifford Lane, Deputy Director for Clinical Research and 13:00-13:10 PS1/01 Overview of the impact of COVID-19 on progress toward the SDG targets Special Projects , National Institute of Allergy and Infectious Diseases (NIAID), USA A.R. Stengaard1, A. Sullivan2, J.D Kowalska3, C. Rokx4, D. Impact of the COVID-19 pandemic on linkage to and retention in care for HIV, hepatitis B and C and 13:10-13:20 PS1/02 Raben1, D. Simões5, The EuroTEST COVID-19 impact sexually transmitted infections in the WHO European Region assessment consortium of partners s.a.m Health: Germany’s first digital sexual health service is providing COVID-safe remote STI testing and A. Schafberger1, K.M. Dymek2, G. Waltinger3, G. Davies4, 13:20-13:30 PS1/03 counselling during the Covid-19 Pandemic and beyond C. Kantwerk1 Rapid HIV testing and linkage in rehabilitation centers during COVID-19 pandemics, Yekaterinburg and V. Evseeva1, M. Greysman1, V. Stanilevskiy2, N. 13:30-13:40 PS1/04 Sverdlovsk region, Russia Mironova2, A. Chuykov3, A.M. Żakowicz3 13:40-13:50 PS1/05 European testing week: adaptation of testing services during the COVID-19 pandemic B. Collins1, C. Bom Kahama2, D. Raben2 13:50-14:15 Discussion 14:15-14:30 Break Moderators: 14:30-15:30 AS1 ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage Cary James, World Hepatitis Alliance Valerie Delpech, Public Health England L. Cosmaro1, D. Savarino1, M. Mommi2, Z. Dominkovic3, A. 14:30-14:37 AS1/01 RiskRadar: the 1st integrated ICT tool on combination prevention for hepatitis/HIV/TB/STI Simkunaite-Zazecke4, L. Stoniene5, A. Raahauge6, C. Kakalou7, V. Drosou8, P. Natsiavas7 An evaluation of the outcomes of an online HIV self-sampling service to inform risk communication and J. Taylor1,2, G. Holdsworth1, S. Amos-Gibbs1, E. Ardines1, B. 14:37-14:44 AS1/02 future online testing policy George1, J. Harbottle1, P. Baraitser1,3 Efficacy of an on-screen computer reminder for HIV screening in primary care based on indicator C. Agustí1,2, O. Cunillera3, J. Almeda3, J. Mascort4,5, R. 14:44-14:51 AS1/03 conditions: a cluster randomized controlled trial Carrillo4,5, C. Olmos3, J. Casabona1,2 Breaking the Chain? A once in a generation opportunity to find and treat HIV during UK’s COVID-19 14:51-14:58 AS1/04 A. Basu1, B. George1, G. Holdsworth1 lockdown 14:58-15:30 Discussion E-poster sessions (live Q&A)/break: 15:30-16:30 PO1: Innovative testing services during the COVID-19 pandemic: lessons learned PO2: Impact of COVID-19 on provision of services for people who inject/use drugs

3

PO3: New testing technologies to increase testing coverage: HIV self-testing and home-based sampling Moderators: Ben Collins, ReShape/International HIV Partnerships 16:30-17:45 PS2 PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB Teymur Noori, European Centre for Disease Prevention and Control (ECDC) Claudia Estcourt, Glasgow Caledonian University, 16:30-16:40 PS2/01 “Prevention is hard, Combination is key” – Good example of HIV/STI combination prevention in Scotland Scotland, 16:40-16:50 PS2/02 Combination disease prevention in prisons: a comprehensive programme in Luxembourg Patrick Hoffmann, Luxembourg Directorate of Health 16:50-17:00 PS2/03 TB an HBV/HCV/HIV-combined preventive activities in the Netherlands Gerard de Vries, RIVM, Netherlands E. Smout1, J. Williams2, A. Miners2, K. Phyu3, L Parker3, A The ‘Get Tested LeEDs’ project: clinical impact and cost-effectiveness of opt-out emergency department 17:00-17:10 PS2/04 Evans3, J McLaren3, M. Aldersley3, G. Hughes1, M. Ruf4, E. testing for bloodborne viruses (BBVs) in England Page3 17:10-17:45 Discussion 17:45-18:00 Break Moderators: 18:00-19:30 EU Health Project Symposium: lessons learned from the INTEGRATE Joint Action Luis Mendão, GAT Portugal Dorthe Raben, CHIP/INTEGRATE Coordinator 18:00-18:05 The INTEGRATE Story & INTEGRATE at HepHIV Dorthe Raben, CHIP/INTEGRATE Coordinator 18:05-18:30 Video presentation of the processes behind the main outcomes of the INTEGRATE JA Short intro to the Online training module on prevention, testing and linkage to care 18:30-19:30 Panel discussion: Integration of Infectious Diseases – keeping the momentum Valerie Delpech, Public Health England Lella Cosmaro, Lila Milano Jordi Casabona, El Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT) Ann Sullivan, SSAT Chelsea Westminister Hospital Nadia Gasbarrini, Villa Maraini Jack Lambert, University of Dublin & Mater Misericordiae University Hospital Walter Cullen, University of Dublin Jeff Lazarus, Barcelona Institute for Global Health (IS Global) Teymur Noori, European Centre for Disease Prevention and Control (ECDC) Thomas Seyler, EMCDDA Ana Gutierrez Burgos, DG SANTE

4

Friday 7 May 2021

Time (CET) Session Moderators and Speakers Moderators: Jordi Casabona, El Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya 13:00-14:15 PS3 PLENARY/ABSTRACT DRIVEN SESSION 3: Implementing integrated testing strategies (CEEISCAT) Anastasia Pharris, European Centre for Disease Prevention and Control (ECDC) 13:00-13:10 Short report from Conference Day 1 Conference chairs Raimonda Matulionytė, Vilnius University Hospital 13:10-13:20 PS3/01 Experience in innovative approach to testing for HIV, hepatitis and STIs Santaros Klinikos, Lithuania Maka Danelia, National Center for Disease Control and 13:20-13:30 PS3/02 Integrated screening for TB, HIV and HCV at the primary healthcare level Public Health, Georgia Evolution of key indicators for community-based voluntary counseling and testing activity in Europe: M. Gogishvili1, L. Fernàndez López1,2,3, J. Casabona 13:30-13:40 PS3/04 COBATEST Network 2017-2019 Barbarà1,2,3 13:40-13:50 PS3/05 Implementing self-test programmes during COVID-19 Robert Hejzak, Czech AIDS Help Society 13:50-14:15 Discussion 14:15-14:30 Break Moderators: 14:30-15:30 AS2 ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD Eberhard Schatz, Correlation Network Lella Cosmaro, Lila Milano, Italy Testing and linkage to care services for 1000 people who inject drugs from Bucharest through the 14:30-14:37 AS2/01 S. Ciobanu1, A. Bocai1, M. Dan1, A. Luca1, R. Teodorescu1 implementation of a three level HCV elimination strategy S. Shirley-Beavan1, R. Csak1, C. Daniels1, N. Burke-Shyne1, Integrated harm reduction responses to HIV and viral hepatitis in the COVID-19 pandemic: a global 14:37-14:44 AS2/02 G. Lasco2, M. Platko3, J. di Iorio4, C. Ahumada4, S. Hajal5, E. overview Aaraj5, C. Baguma6, K. Naik7 S. Mazzilli1,2, T. Sebastiani3, V. Casigliani1, G. Cocca3, A. 14:44-14:51 AS2/03 Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan, Italy Stemat3, C. Nicola3, C. Selva3, C. Catani3, L. Tavoschi1, R. Ranieri3 E. Emanuel1, S. Croxford1, E. Phipps1, A. Ibitoye1, J. 14:51-14:58 AS2/04 Blood-borne virus testing in people who inject drugs with a history of sex work Njoroge1, C. Edmundson1, L. Slater1 14:58-15:05 AS2/05 HCV care for PWID in Europe - results from a civil society-led monitoring R. Rigoni1, T. Tammi2, E. Schatz1

15:05-15:30 Discussion

5

E-poster sessions (live Q&A)/Break: PO4: Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings 15:30-16:30 PO5: Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings PO6: Models of testing and linkage to care for people who inject/use drugs Moderators: Anne Bergenström, European Monitoring Centre for 16:30- 17:45 PS4 PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC) Drugs and Drug Addiction (EMCDDA) Viktor Mravčík, Head of the National Monitoring Centre for Drugs and Addictions, Czechia 16:30-16:40 PS4/01 Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: European perspectives Thomas Seyler, EMCDDA 16:40-16:50 PS4/02 New evidence on testing and linkage to care for PWIDs Otilia Mardh, European Centre for Disease Prevention and Control (ECDC) 16:50-17:00 PS4/03 Ensuring delivering of testing and linked services for PWID/PWUD during the COVID19 pandemic Marios Atzemis, Positive Voice, Greece 17:00-17:10 PS4/04 What is needed to promote prisons as a setting for case-finding and treatment of infections among PWIDs? Fadi Meroueh, Montpellier University Hospital, France 17:10-17:45 Panel Discussion Moderator: Linda Montanari, EMCDDA 17:45-18:00 Break 18:00-19:15 CLOSING SESSION: Integrating disease areas and settings Moderator: Session objectives: Michel Kazatchkine, Special Advisor to the Joint United • To discuss lessons learned and next steps for integration of service delivery in infectious diseases Nations Program on AIDS (UNAIDS) for Eastern Europe • To present + discuss the conference Call to Action & implications for policy & implementation agendas and Central Asia 18:00-18:15 Short report from Conference Day 2 and Best Poster Award Jürgen Rockstroh, HepHIV2021 Conference Co-chair, HIV Outpatient Clinic, University of Bonn, Germany 18:15-19:05 Panel Discussion: Integrated testing and linkage to care for HIV, viral hepatitis, TB, STIs and other Panellists: infectious diseases: Paving the way forward amidst a global pandemic Cary James, World Hepatitis Alliance Andrew Winter, IUSTI Europe Jens Lundgren, CHIP, University of Copenhagen Nicole Seguy, WHO Regional Office for Europe Yazdan Yazdanpanah, ANRS Maladies Infectieuses Emergentes, France Nikoloz Chkhartishvili, Infectious Diseases, AIDS & Clinical Immunology Research Center (IDACIRC), Georgia Paul Sommerfeld, TB Europe Coalition Nikos Dedes, European AIDS Treatment Group (EATG) Ricardo Baptista Leite, MP Portugal, UNITE 19:05-19:15 Conference Call to Action and closing remarks Daniel Simões, HepHIV2021 Conference Co-chair, Coalition Plus/GAT, Portugal

6

POSTER PROGRAMME

Thursday & Friday, 6-7 May 2021 Live Q&A & On Demand

Poster Session 1 (PO1): Innovative testing services during the COVID-19 pandemic: lessons learned L. Fernàndez-López1,2, Impact of the COVID-19 pandemic on community-based testing for HIV, viral hepatitis and sexually transmitted PO1/01 D. Simões3,4, M. Krone5, infections in the WHO European Region J. Casabona1,2 F. Barata1, C. Pereira1, I. Pereira1, Screening, diagnosis and treatment of HCV/HIV during the COVID 19 pandemic: lessons from a Mobile PO1/02 H. Faria1, R. Sousa Coutinho1, D. Gil Outreach Program in Lisbon, Portugal Morais1 A.L. Rosa1, P. Morais1, E. Sávio1, PO1/03 Impact of COVID-19 on a Portuguese ONG screening site: implications for practice J. Conceição1, C. Rodrigues1 Strengthening community responses on prevention and care for PLHIV and key populations during the COVID- M. Reiriz Rojas1, A. Bertó Moran1, PO1/04 19 emergency crisis D. García Morcillo1 Going cashless in a cash-constrained crisis: Implementation of a COVID-19 emergency response program for PO1/05 T. Anand1, C. Nitpolprasert1 optimising engagement in HIV care among Thai men who have sex with men and transgender women Use of mobile applications and social networks for HIV testing among MSM and PrEP obtaining at COVID-19 A. Chernyshev1, A. Bogoslavets1, PO1/06 conditions, in Ukraine R. Marchenko1

Poster Session 2 (PO2): Impact of COVID-19 on provision of services for people who inject/use drugs S. Croxford1, E. Emanuel1, Changes to the provision of services for people who inject drugs in England, Wales and Northern Ireland during PO2/01 A. Ibitoye1, J. Njoroge1, C. the COVID-19 pandemic Edmundson1, L. Slater1, E. Phipps1 COVID-19 impact on harm reduction programs (testing and counselling) in low threshold drug services in A. Krings1, G. Steffen1, C. PO2/02 Germany Germershausen1, R. Zimmermann1 A. Herranz1, À. Vilella2, A. Agius3, The impact of the COVID-19 pandemic on harm reduction services in a prison and addiction centres in the J.M. Alonso4, A. Rodríguez5, PO2/03 Balearic Islands, Spain: preliminary results from a novel hepatitis C elimination programme C.A Picchio1, D. Guy1, C. Pujol1, M. Buti6,7, J. Lazarus1 J.S. Lambert1,2, B. West2, PO2/04 Using peer support to facilitate hepatitis C treatment during the COVID-19 pandemic T. McHugh1, J. Farrell2, C. Moran2, l. Vidal1

7

Poster Session 3 (PO3): New testing technologies to increase testing coverage: HIV self-testing and home-based sampling Key learnings from an HIV at-home testing campaign for Dutch MSM and trans people during the COVID-19 K. Vermey1, P. Zantkuijl1, H. Bos1, PO3/01 pandemic M. Lasschuyt2, K. Visser2, W. Zuilhof1 M. Ankiersztejn-Bartczak1, PO3/02 Self HIV testing in Poland implementation during COVID-19 A. Stola1,2 N. Bogdanić1, D. Dubravić2, Preliminary results of a pilot project on HIV self-testing among men who have sex with men in the City of Zagreb, PO3/03 J. Kresović2, M. Erceg2, A. Dišković2, Croatia, 2020/2021 T. Beganović2, Š. Zekan1, J. Begovac1 Get an HIV test at home! Increasing access to testing, in the pandemic context, by implementing a pilot program M. Lixandru1, S. Ciobanu1, PO3/04 of home-based HIV testing in Romania C.-L. Hanu1, A. Schiau1 C. Agustí1,2, H. Martínez1, E. Martró3,2, S. Moreno1, E. Muntada1, TESTATE C Plus: an online self-sampling intervention for hepatitis C in gay, bisexual and other men who have P. Romano1, L. Egea1, R. Mora4, PO3/05 sex with men and trans women in Catalonia (Spain) L. Villegas4, J. Mena4, Q. Roqueta5, J. Hernández6, M. Vázquez6, A. Not3, A. Pérez3, J. Colom7, J. Casabona1,2 C. Agustí Benito1,2, H. Martínez1, High acceptability and effectiveness of an online self-sampling intervention for HIV in gay, bisexual and other V. González1, S. Moreno1, PO3/06 men who have sex with men and trans women in Spain (TESTATE VIH) E. Muntada1, P. Romano1, L. Egea1, R. Muñoz1, J. Hoyos3,2, J. Casabona1,2 Poster Session 4 (PO4): Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings C. Folch1, A. Díaz2, M.C. Vázquez3, PO4/01 Socio-demographic inequalities in HIV testing patterns among MSM in Spain S. Meyer4, J. Casabona1 J. Llaneras Artigues1, A. Barreira- Díaz1, A. Rando Segura1, J. Bañares Sanchez1, B. Meza Ramos1, L. Ruíz Ortega1, J.R. Marques Soares1, Towards a hepatitis C-free hospital: results after one year of hepatitis C virus screening in a tertiary hospital PO4/02 A. Monforte Pallares1, O. Orozco emergency department in a high-income country Gálvez1, M. Riveiro-Barciela1, F. Velasquez Orozco1, F. Rodríguez- Frías1, M. Arranz Betegon1, R. Esteban Mur1, M. Buti Ferret1 S. Semikova1, P. Supronenko2, PO4/03 Implementation of HIV rapid testing model in government medical facilities in Leningrad Region, Russia in 2020 V. Stanilevskiy2, M. Petrova3, 8

O. Prokof’eva4, V. Surkova5, A. Merzlyakova6, Y. Godunova6, A. Kovelenov1, A. Chuykov2, N. Mironova2, A. Zakowicz7 J. Lazarus2, M. Kall1, U. Fresán2,3, D. Guy2, G. Brown4, C. Burgui5, PO4/04 Quality of life in people living with HIV in Romania and Spain J. Castilla5, V. Ionel Grecu6, F. Dumitrescu6, V. Delpech1 M. Riveiro-Barciela1,2, B. Treviño3, N. Serre3, A. Rando4, F. Salvador3, HCV screening of immigrants at arrival: an opportunity to linkage to care of a population with limited access to A. Barreira-Díaz1, A. Palom1, PO4/05 Health Care system E. Vargas1, D. Pou3, L. Roade1,2, I. Molina3, F. Rodríguez-Frías2,4, M. Buti1,2 L. Stoniene1, E Subata1, Expanding integrated HCV/HIV testing to alcohol dependent clients attending treatment centres for drug and A Sirvinskiene1, A Grice1, PO4/06 alcohol dependency in Lithuania M.L. Jakobsen2, S. Finne Jakobsen2, D. Raben2, C. Rae3, A. Sullivan3 S. Strachan1,2, S. Jaffer1, V. Apea3, D. Campbell4, J. Domino5, L. Davies1, PO4/07 Distributing a questionnaire for women attending a Sexual Health Clinic increases PrEP uptake J. Dugdale6, K. Nambier7, D. Onyago8, J. Otti2, M. Ross9, J. Stevenson2, N. Turner1, G. Singh1, A. Sullivan1 HIV and viral hepatitis transmission knowledge among female health care providers and females in the general A.-M. Schweitzer1, M. Bogdan1, PO4/08 population in Constanta Region, Romania F.S. Stoian1, I. Ciocea1 Poster Session 5 (PO5): Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings Community-based voluntary counseling and testing for HIV, sífilis and HCV in Europe: COBATEST Network M. Gogishvili1, L. Fernàndez PO5/01 2019 López1,2,3, J. Casabona Barbara1,2,3 G. Dessì1, F. Cardinale1, V. Mascia1 PO5/02 Rapid Hiv test in Sardinia, a lookback at first 5 years of Lila Cagliari testing service

M.E. Saraiva1, S. Melo Refoios1,2, Reaching 95-95-95: 3 years of the Portuguese League Against AIDS performing screening tests and promoting PO5/03 M. Ferrão1, G. Bento3, R. Castro4, therapeutical compliance R. Vicente5, L. Nunes5 Promoting autonomy and self-care of people living with HIV and/or hepatitis through a community-based A.-S. Petit1,2, J.-P. Dada3, L. Napuchi3, PO5/04 approach: the example of the Takari project in French Guiana C. Mathurin4, M. Shahisavandi4, 9

M. Préau1, D. Michels2,5, M. Gaillet6, C. Michaud6, C. Piedrafita y Costa3 Contributions of (+) Screening = (+) Life Project in the access of the Trans and Sex Worker population to early P. Costa1, F. Aguiar1, S. Correia1, PO5/05 detection and screening of STIs A. Silva2, P. Belmonte1, F. Neves3

Poster Session 6 (PO6): Models of testing and linkage to care for people who inject/use drugs Point-of-care screening combined with nursing and peer-based outreach work to enhance testing and C. Merendeiro1, R. Lopes1, I. Marinho1, PO6/01 treatment for hepatitis C among people who use drugs, people who experience homelessness, and migrants: R. Marinho2, J. Grebely3, A. Nave1 the REACH U Study E. Borzunova1, A. Chernov2, PO6/02 Efficiency of HIV rapid testing and social services for IDU women in Tomsk, Russia V. Stanilevskiy3, N. Mironova3, A. Chuykov4, A.M. Żakowicz4 O. Anagnostou1, K. Micha1, K. Kaliva1, E. Tsirogianni1, E. Petroulaki1, I. Detsi1, M. Kollitsida1, G. Androulakis1, M. Gargoulaki1, V. Karagounis1, Hepatitis C cascade of care (CoC) for people who use drugs (PWUD) under opiate substitution treatment A. Katsili1, S. Kollia1, A. Kotsalis1, PO6/03 (OST) in Greece M. Spirellis1, K. Stamatopoulos1, V. Stavridou1, C. Tanis1, P. Tsekoura1, Y. Topalidou Stepin1, A. Tsantilas1, M. Chalkiadakis1, A. Drimousi1, N. Papadopoulos2, A. Theocharis1 Á. Ávila1, T. Azevedo1, M.J. Braz1, S. Busi1, F. Calinas2, R. Costa1, PO6/04 Decentralized HCV consultation: an HCV micro-elimination project in the community T. Mamede1, C. Marques1, R. Pires1, J. Santa Maria1 H. Taylor1, A. Curado1, Â. Leite1, J. Pires2, V. Correia1, P. Nunes2, PO6/05 Portugal’s first mobile drug consumption room: client characteristics and linkage to care J. Caldas1, M. Alves2, J. Canêdo1, D. Gautier2 I. Gountas1, G. Nikolopoulos2, PO6/06 Could the 2010 HIV outbreak in Athens, Greece be prevented? A mathematical modelling study G. Touloumi3, A. Fotiou4, K. Souliotis1 Eliminating hepatitis C on the Balearic Islands by linking patients who use drugs from addiction service centers, J.V Lazarus1, À. Vilella2, C.A Picchio1, PO6/07 a local NGO, a prison and a mobile methadone bus to HCV care A. Herranz1, M. Buti3,4

10

J. Valencia1, P. Ryan1, J. Lazarus2, Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for PO6/08 J. Troya1, G. Cuevas1, I. Cañamares1, HIV-positive people who use drugs (PWUD) I. Escobar1 J. Palacio-Vieira1,2, J.M. Reyes- Urueña1,2,3, A. Imaz4, A. Bruguera1,3, L. Force5, A.-J. Orti-Llaveria6, J.-M Llibre7, I. Vilaró8, F. Homar PO6/09 Designing a strategy to reengage PWID lost to follow-up in HIV care, the case of the PISCIS Cohort in Spain Borràs9, V. Falcó10,11, M. Riera12, P. Domingo13, E. de Lazzari14, I. Chivite14, E. Letang15, J.-M Miró14, J. Casabona1,2,3,16 M. Vasileiou1, O. Anagnostou2, I. PO6/10 Impact of opiate substitution treatment (OST) on hepatitis and HIV high risk behaviors Elefsiniotis3

11